著者

市川 良之 井本 祥子 中島 築 海野 徳二 白戸 勝 川堀 真一 高橋 光明 中村 晃 熊井 恵美 野中 聡 長島 泰行 金井 直樹

出版者

The Society of Practical Otolaryngology

雑誌

耳鼻咽喉科臨床 補冊 (ISSN:09121870)

巻号頁・発行日

vol.1987, no.15, pp.86-94, 1987

被引用文献数

1

---

A clinical evaluation was conducted on 107 patients with laryngeal cancer treated in our department between 1976 and 1985. Their mean age was 64.0 years, and the male to female ratio was 12: 1. Histopathologically, squamous cell carcinoma was the most common malignant tumor constituting 97.2% of all the cases, whereas there were only 3 cases of verrucous carcinoma. There were 52 cases of glottis,52of supraglottis and 3 of subglottis. The overall five-year survival rate was 62.7%. The five-year survival rates for Stages I to IV were 74.6%,84.9%,54.2% and 31.1%, respectively. As the five-year survival rate of T4 cases was 0%, more aggresive therapies such as combinations of extended operation, irradiation and chemotherapy appear to be required in such cases. In our clinic, the patients with metastases to the cervical lymph nodes at preoperation were treated with radical neck dissection combined with the total laryngectomy in most cases. Radical neck dissection for such patients decreases the number of death due to uncontrolled metastases to the cervical lymph nodes. In the cases of the advanced stage, careful postoperative examination is required.

著者

山崎 勤 小川 勝比古 山川 宗位 山中 昇 白戸 勝 柳内 統 吉田 真子 山本 一男 福田 勝洋

出版者

耳鼻と臨床会

雑誌

耳鼻と臨床 (ISSN:04477227)

巻号頁・発行日

vol.34, no.4, pp.987-1007, 1988-07-20 (Released:2013-05-10)

参考文献数

27

---

The clinical effect of isosorbide (TYS) for patients with Ménière's disease was first reported in 1981. Long-term treatment by TYS produced considerable symptomatic relief in many patients during the active stage of the disease. In the present study, the effect of TYS for patients with Ménière's disease was evaluated by a multi-centered double blind trial using betahistine meyslate (MR) as a reference drug over a period of 8 weeks. The indices that reflect global improvement and utility showed, by the Wilcoxon rank sum test (one-tailed), that the TYS was significantly (P<0.05) superior to the MR in the effectiveness of the control of Ménière's disease at 2 weeks, 4 weeks, 6 weeks and 8weeks after administration. There was no particular difference in the frequencies of side effects or abnormal clinical laboratory findings between groups treated with TYS and with MR. From the above results, it was concluded that TYS was an effective and useful drug for the treatment of Ménière's disease.